Thera-SAbDab

MILATUZUMAB

>   Structural Summary
TherapeuticMilatuzumab
TargetCD74
Heavy ChainQVQLQQSGSELKKPGASVKVSCKASGYTFTNYGVNWIKQAPGQGLQWMGWINPNTGEPTFDDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCSRSRGKNEAWFAYWGQGTLVTVSS
Light ChainDIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-I/II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2007
INN Year Recommended2008
Companies InvolvedImmunomedics
Conditions Approvedna
Conditions ActiveSystemic lupus erythematosus
Conditions DiscontinuedGraft-versus-host disease, Haematological malignancies, Chronic lymphocytic leukaemia, Multiple myeloma, Non-Hodgkin's lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]